A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Public ClinicalTrials.gov record NCT03329950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
Study identification
- NCT ID
- NCT03329950
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 132 participants
Conditions and interventions
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Breast Cancer
- Gastric Cancer
- Renal Cell Carcinoma
- Ovarian Cancer
- Cholangiocarcinoma
- Bladder Urothelial Carcinoma
- Pancreatic Adenocarcinoma
- Colorectal Cancer
- Esophageal Cancer
- Hepatic Cancer
- Head and Neck Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Other Solid Tumors
- Diffuse Large B-cell Lymphoma (DLBCL)
- Mantle Cell Lymphoma
- Indolent B-cell Lymphomas
- Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Waldenstrom's Disease
- Marginal Zone Lymphoma
- Mucosa Associated Lymphoid Tissue
- Small Lymphocytic Leukemia
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2017 (Actual)
- Primary completion
- Sep 13, 2022 (Actual)
- Completion
- Sep 13, 2022 (Actual)
- Last update posted
- Mar 28, 2024
2017 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Insititute | Scottsdale | Arizona | 85258 | — |
| Northside Hospital, Inc. | Atlanta | Georgia | 30342 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Gabrail Cancer Center Research LLC | Canton | Ohio | 44718 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Abramson Cancer Center at the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Rhode Island Hospital (RIH) The Miriam Hospital (TMH) | Providence | Rhode Island | 02903 | — |
| Houston Methodist | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03329950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2024 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03329950 live on ClinicalTrials.gov.